Novartis AG
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis New Drug Approvals in 4 Key Regulatory Markets by Year
New Drug Approvals in 4 Key Regulatory Markets (Approvals — US, EU, Japan, China)
Novartis New Drug Approvals in 4 Key Regulatory Markets: 29 in FY2025, up 45.0% from a year earlier.
Where the FY2025 figure comes from
“| Approvals (US, EU, JP, China) | 29 | 20 | 36”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025 & Public Commitments.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | New Drug Approvals in 4 Key Regulatory Markets (Approvals — US, EU, Japan, China) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29 | +45.0% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 20 | -9.1% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 22 | -4.3% | Novartis Form 6-K (0001370368-25-000008) ↗ |
| FY2022 | Dec 31, 2022 | 23 | +9.5% | Novartis Form 6-K (0001370368-25-000008) ↗ |
| FY2021 | Dec 31, 2021 | 21 | -19.2% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2020 | Dec 31, 2020 | 26 | – | Novartis Form 6-K (0001370368-23-000009) ↗ |
Breakdown
What makes up new Drug Approvals in 4 Key Regulatory Markets
Cite this data
StockData. (2026). Novartis New Drug Approvals in 4 Key Regulatory Markets, annual FY2020–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rd-approvals-major-markets
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.